Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization


Submitted: 18 November 2014
Accepted: 18 November 2014
Published: 31 August 2012
Abstract Views: 1023
PDF: 986
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • A.A. Zuppa Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • G. Alighieri Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • A. Fracchiolla Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • P. Catenazzi Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • A. D’Antuono Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • R. Riccardi Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • M. Cavani Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
  • C. Romagnoli Dipartimento di Pediatria, Divisione di Neonatologia, Università Cattolica del Sacro Cuore, Roma, Italy.
Objectve. The Rh-hemolytic disease can lead to a late anemia by hemolytic and hyporigenerative mechanism. We compared the effectiveness of rHuEPO in two care protocols that differ for doses of rHuEPO administrated and for timing of administration. Methods. A cohort of 14 neonates was investigated. The neonates were treated with two different protocols. Protocol A: a dose of 200 U/kg/day of rHuEpo administered subcutaneously starting from the end of the second week of life; Protocol B: a dose of 400 U/kg/day of rHuEpo administered subcutaneously starting from the end of the first week of life. Results. The hematocrit values in the protocol A group decreased during treatment (32,5% vs 25,2%), whereas the hematocrit value in protocol B group remained almost stable (38,7% vs 42,8%). The mean numbers of platelets remained stable in both groups while neutrophils increased in protocol A group and decreased in protocol B (p<0,05). Reticulocyte count increased during treatment in both groups, although only in protocol B group it was statistically significative (p<0,05). Conclusions. Our results suggest a similar efficacy between the two treatment protocols. Increasing doses of rHuEPO do not seem enhancing their effectiveness and the incidence of side effects.

Zuppa, A., Alighieri, G., Fracchiolla, A., Catenazzi, P., D’Antuono, A., Riccardi, R., Cavani, M., & Romagnoli, C. (2012). Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization. La Pediatria Medica E Chirurgica, 34(4). https://doi.org/10.4081/pmc.2012.72

Downloads

Download data is not yet available.

Citations